We use cookies to ensure that we give you the best website experience. By continuing to use this site, you are agreeing to our use of cookies.



One of Kyowa Kirin International’s strengths has always been the depth of knowledge and experience in its multidisciplinary team of development professionals whose track record covers all aspects of research and research, development, regulatory and pharmacovigilance. The development function is based at Kyowa Kirin International’s UK headquarters and in the company’s US office in New Jersey.

The development team has a significant track record of success including approvals for:

  • Adcal –D3 (UK)
  • Sancuso (US)
  • Abstral (US & EU)
  • Rectogesic / Rectiv (US & EU)
  • Tostran / Fortesta (US & EU)

Since Kyowa Kirin International’s acquisition by Kyowa Hakko Kirin (KHK) in April 2011, Kyowa Kirin International’s development team has been focusing on bringing KHK’s valuable pipeline of high technology medicines to market in both Europe and the US. Multidisciplinary teams from Kyowa Kirin International have been working closely with their KHK colleagues in Japan and the US to develop the products in the KHK pipeline and to assess the most appropriate route to market in the EU and US for these products.

Click here to view the current status of KHK’s product pipeline.